CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
68Ga-DOTATOCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03136328
NCT03136328Phase 3Completed
CompareCT.gov

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Montefiore Medical Center·interventional·Posted May 2, 2017·Updated May 9, 2023

In Brief

A Phase 3 clinical trial evaluating 68Ga-DOTATOC for Neuroendocrine Tumors. Completed, enrolled 11 participants.

Detailed Summary

The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
Countries--
CollaboratorsNCM USA

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2, 2017
Enrollment StartMay 16, 2016
Primary CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.2 years ago

Interventions

68Ga-DOTATOCdrug

The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.